COMPARISON OF 3 DIFFERENT IMMUNOASSAYS FOR THE DETERMINATION OF CA 19-9 IN PANCREATIC CANCER PATIENTS - A NEW ASPECT OF POTENTIALLY CLINICAL RELEVANCE

被引：0
|
作者：
Klapdor, R. [1 ]
Bahlo, M. [1 ]
机构：
[1] ZeTDT GmbH, Internal Unit, Hamburg, Germany
来源：
ANTICANCER RESEARCH | 2014年 / 34卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
328
引用
收藏
页码：5998 / 5999
页数：2
相关论文
共 50 条
  • [41] Prognostic value of CA 19-9 serum course in pancreatic cancer
    Safi, F
    Schlosser, W
    Falkenreck, S
    Beger, HG
    HEPATO-GASTROENTEROLOGY, 1998, 45 (19) : 253 - 259
  • [42] CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer
    Ishii, H
    Okada, S
    Sato, T
    Wakasugi, H
    Saisho, H
    Furuse, J
    Ishikawa, O
    Matsuno, S
    Yokoyama, S
    HEPATO-GASTROENTEROLOGY, 1997, 44 (13) : 279 - 283
  • [43] EVALUATION OF CA 19-9 LEVELS AS A MARKER FOR PANCREATIC-CANCER
    SHAW, NY
    HUTTON, JM
    DALBOW, MH
    SWANSON, PA
    BORDEN, KK
    CLINICAL CHEMISTRY, 1987, 33 (06) : 1034 - 1034
  • [44] ELEVATED CA 19-9 PREDICTS UNRESECTABLE PANCREATIC-CANCER
    LAMBIASE, L
    VOGEL, SB
    FORSMARK, CE
    GASTROENTEROLOGY, 1993, 104 (04) : A418 - A418
  • [45] Extremely high level of CA 19-9 in a patient with metastatic pancreatic cancer: Second highest level of CA 19-9 in literature
    Kizilarslanoglu, Muhammet Cemal
    Civelek, Ramazan
    Kilic, Mustafa Kemal
    Kerem, Mustafa
    Gunaydin, Yusuf
    Ulger, Sukran
    JOURNAL OF BUON, 2014, 19 (02): : 583 - 584
  • [46] Old Dog, New Tricks: Use of CA 19-9 for Early Diagnosis of Pancreatic Cancer
    Modi, Shrey
    Kir, Devika
    Saluja, Ashok Kumar
    GASTROENTEROLOGY, 2021, 160 (04) : 1019 - 1021
  • [47] Doubling time of serum CA 19-9 in the clinical course of patients with pancreatic cancer and its significant association with prognosis
    Nishida, K
    Kaneko, T
    Yoneda, M
    Nakagawa, S
    Ishikawa, T
    Yamane, E
    Nishioka, B
    Miyamoto, Y
    Takano, H
    Yoshikawa, T
    Kondo, M
    JOURNAL OF SURGICAL ONCOLOGY, 1999, 71 (03) : 140 - 146
  • [48] CA 19-9 as a Predictor of CT Response for Patients With Locally Advanced Pancreatic Cancer (LAPC)
    Moskovic, D. J.
    Carlson, P.
    Dakik, H.
    Qiao, W.
    Javle, M.
    Fogelman, D. R.
    PANCREAS, 2009, 38 (08) : 1029 - 1029
  • [49] CA 19-9 AS A PREDICTOR FOR RESPONSE AND SURVIVAL IN ADVANCED PANCREATIC CANCER PATIENTS TREATED WITH CHEMORADIOTHERAPY
    Koom, Woong Sub
    Seong, Jinsil
    Kim, Yong Bae
    Pyun, Hae Ok
    Song, Si Young
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (04): : 1148 - 1154
  • [50] CA 19-9: A surrogate to assess response to treatment in patients with metastatic pancreatic cancer (MPC).
    Diaz, Celso L.
    Cinar, Pelin
    Hwang, Jimmy
    Ko, Andrew H.
    Tempero, Margaret A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345